Semaglutide improves cognition in HIV patients significantly

In a recent study, researchers found that semaglutide, a medication usually used for weight management, may also enhance cognitive function in adults living with HIV. The study involved 108 participants over a period of 32 weeks. Those who received semaglutide injections showed notable improvement in cognitive tests compared to those who received a placebo. HIV can often lead to various health issues, including weight gain and inflammation, which may negatively impact brain function. Dr. Ornina Atieh, a postdoctoral fellow, highlighted these concerns during a presentation at a medical conference. She noted that people with HIV are at a higher risk for cognitive dysfunction related to increased body fat and inflammation. The study was unique as it was the first randomized placebo-controlled trial of its kind, as stated by Dr. Grace A. McComsey, a senior author. It specifically aimed to investigate how semaglutide affects neurocognitive health while also addressing issues of weight gain and inflammation in patients with HIV. Participants underwent cognitive assessments before and after the 32-week treatment period. Results indicated significant improvements in specific cognitive areas for those receiving semaglutide, particularly in visuospatial skills. However, the team found that the improvements were not linked to weight loss or changes in inflammation levels, which surprised the researchers. Despite promising results, the study's authors noted some limitations. The small sample size and short duration of the study restrict the findings' implications. Researchers called for larger, longer studies to better understand semaglutide's effects on cognition in HIV patients. Overall, the results suggest that semaglutide may offer new avenues for treating cognitive difficulties in people living with HIV. However, further research is needed to confirm these findings and explore effective treatment options for both cognitive dysfunction and associated physical health issues.